| Pipeline
page,page-id-14,page-template-default,ajax_updown_fade,page_not_loaded,,qode-title-hidden,qode-child-theme-ver-,qode-theme-ver-9.5,wpb-js-composer js-comp-ver-4.12,vc_responsive


Vaccibody is currently testing it’s lead product candidate, VB10.16, to treat HPV16-induced precancerous cervical lesions in a clinical phase I/IIa study.


Strong preclinical data for a range of indications have been obtained and future Vaccibody cancer vaccines are under preclinical development.

The company’s first product candidate VB10.16 is a DNA based immunotherapy targeting malignancies caused by Human Papilloma Virus 16 (HPV16). HPV16 is a major contributor to several cancers, including Cervical, Vulvar, Anal and Head and Neck Cancer. Vaccibody is currently enrolling patients in a proof of concept study in patients with HPV16 induced pre-malignancies of the Cervix (Cervical Intraepithelial Neoplasia). See: for more information.


Earlier stages of HPV16 infection as well as other cancers induced by HPV may be treated with the same vaccine. A clinical proof of concept with Vaccibody’s first candidate VB10.16 may therefore open up for opportunities in a number of cancer indications.


Vaccibody has compelling preclinical data in a range of animal models within cancer and infectious diseases including Vaccines against Melanoma, Prostate Cancer, B Cell Lymphoma, Multiple Myeloma, Influenza, Herpes Simplex Virus 2, HIV, Ebola and Tuberculosis. In all studies performed, the Vaccibody Vaccine Targeting Platform Technology has shown better results than any of the comparators tested at much lower vaccine doses.


Partnering or new funding will be sought for further development of Vaccibody Vaccines for other cancer indications and/or infectious diseases.